Sagimet
2 known investors
Sagimet is a clinical-stage biopharmaceutical company developing FASN (fatty acid synthase) inhibitors targeting metabolic and fibrotic disease pathways driven by overproduction of the fatty acid palmitate. Its lead candidate, denifanstat, is an oral, once-daily selective FASN inhibitor being developed for conditions including acne, MASH, and certain FASN-dependent tumors.
BiotechHealthtech